ÂÜÀòÂÒÂ×

Scott Rodig, MD, PhD, is an investigational and diagnostic pathologist at Brigham & Women's Hospital. In addition, he is the Director of the Tissue Biomarker Laboratory of the Center for Immuno-Oncology at Dana-Farber Cancer Institute and a Professor of Pathology at Harvard Medical School. Dr. Rodig's laboratory develops novel methods to capture and quantify essential oncogenic signaling pathways in human cancer using primary tissue samples. Most recently, these efforts have focused on defining local immune responses within tumor microenvironments to better guide immunotherapy. In 2018, Dr. Rodig initiated ImmunoProfile, a CLIA-certified multiplex staining and image analysis assay to quantify PD-1 and PD-L1 expression in clinical samples for patients seen at the Dana-Farber Cancer Institute.